News

Fierce Pharma5h
Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Verona Pharma shares jump with Merck set to acquire company in $10 billion deal
Merck to acquire Verona Pharma for $10 billion, adding COPD drug Ohtuvayre to strengthen respiratory portfolio.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Barchart on MSN5h
What You Need To Know Ahead of Merck's Earnings Release
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Zacks Investment Research on MSN6d
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...
Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda
Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...
The Pharma Letter5d
Big pharma faces new patent cliff as top sellers near end of exclusivity
Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...